Huada Gene's 100 billion-dollar market capitalization pharmaceutical company "collapse" is now only 29.6 billion

On July 14 last year, Huada Gene officially landed on A-shares; on November 14th, the market value exceeded 100 billion yuan, and the share price rose more than 17 times from its offering price, second only to Maotai; on July 16, 2018, 206 million restricted shares were released. Just over a year after the listing, Huada Gene's share price is like a roller coaster ride, the market value of "discount", its related business issues have once again raised questions.Smilled" the market value of small financial reports
In fact, Huada gene at the beginning of the listing of "small financial report big market value" has attracted the attention of the industry, recently, Huada gene's market value continued to shrink, hovering around 30 billion yuan, compared with the peak period fell by about 70%. In 2017, its revenue was RMB2,096 million, up 22.44% YoY, and its net profit was RMB398 million, up 19.66% YoY. Huada Gene's main business is to provide genomics diagnosis and research services for medical institutions, scientific research institutions, enterprises and institutions through genetic testing and analysis. The main operating income comes from the four major sectors of reproductive health, complex diseases, basic scientific research and drug research and development, of which the top three sectors account for up to 95% of total operating income.
July 12, Huada Gene released its 2018 half-year results forecast. According to the earnings forecast, the company's business overall maintained a growth trend, reproductive health, basic research, complex diseases and drug research and development business continued to grow year-on-year. Consolidated revenue is expected to be between $110 million and $120 million, an increase of 23.84% to 35.10% over a year earlier. The net profit attributable to shareholders of listed companies is expected to be RMB195 million to RMB215 million, an increase of 2.06%-12.53% over the same period last year and RMB19,106.05 million a year earlier.three consecutive increases of nearly 200 million, the chairman also can not sit still
July 17, 19, 23, Huada Gene issued three consecutive increase announcements, the total amount of increase of nearly 200 million yuan, the main body of the increase includes the company's chairman, directors, senior executives and so on.
, the largest increase on July 23rd, the cumulative amount of not less than 150 million yuan, the main body of the increase is the actual controller / chairman of the company Wang Jian, the company's director Sun Handsome and controlling shareholder Huada Holdings core management team. For this increase, Huada Gene pointed out in the announcement that the company's actual controller, some directors and the core management team of controlling shareholders this increase in the company's shareholding plan is based on the company's future development prospects of firm confidence and recognition of the company's value, while in order to enhance investor confidence, and effectively safeguard the interests of small and medium-sized shareholders.The Great Cancer of China" is hotly debated
on July 13th, some websites and WeChat Public published a report entitled "China Cancer", in which the non-invasional prenatal genetic testing technology and the company's related business were questioned.
July 14th, Huada Gene issued a clarification announcement in the media, responding to questions about non-invasional prenatal genetic testing technology and whether there was exaggerated propaganda. Huada gene said that compared with the traditional Down's screening technology, non-invasional prenatal gene testing has the characteristics of high accuracy, at present, some countries and regions in the world have non-invasion prenatal gene screening as a first-line screening method. As for whether there is exaggerated propaganda, Huada gene is strictly abide by the requirements of national department regulations, in the relevant non-invasive informed consent to clearly inform the scope of application of non-invasive gene testing and technical limitations. Because noninvasive genetic testing as a screening technique has a false negative risk, in order to protect the subjects, each subject will be purchased test health insurance.
, although Huada gene faces many questions, but its domestic gene testing industry leader status is still indisputable.
, ceo of Huada Gene, said in media reports, "The listing is not for market value, predicting the prevention of tumors is the most important thing Huada Gene wants to do in the future." However, it will take time to give an answer as to whether "gene science and technology will benefit mankind" in the future, as the Huada gene advertises. (Mi Net)